Nektar Presents New Responder Data For Rezpegaldesleukin, A First-In-Class Selective Regulatory T-cell Therapy, In Late-Breaking News Oral Presentation At 2023 EADV Congress
Portfolio Pulse from Benzinga Newsdesk
Nektar Therapeutics (NASDAQ:NKTR) presented new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell therapy, at the 2023 EADV Congress. The data showed dose-dependent efficacy across all endpoints for REZPEG in patients with atopic dermatitis. The therapy was well tolerated with no severe, serious, or fatal adverse events reported. Based on these results, Nektar is initiating two Phase 2 studies in atopic dermatitis and in alopecia areata.
October 13, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nektar Therapeutics presented positive data for its T-cell therapy, REZPEG, at the EADV Congress. The company plans to initiate two Phase 2 studies based on these results.
The positive data presented for REZPEG indicates potential for the therapy's success in treating atopic dermatitis. This could lead to increased investor confidence in Nektar Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100